001     120588
005     20240228145454.0
024 7 _ |a 10.18632/oncotarget.15863
|2 doi
024 7 _ |a pmid:28423600
|2 pmid
024 7 _ |a pmc:PMC5410342
|2 pmc
024 7 _ |a altmetric:19231370
|2 altmetric
037 _ _ |a DKFZ-2017-01017
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Wittig-Blaich, Stephanie
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.
260 _ _ |a [S.l.]
|c 2017
|b Impact Journals LLC
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1533215204_15323
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Next-generation sequencing has dramatically increased genome-wide profiling options and conceptually initiates the possibility for personalized cancer therapy. State-of-the-art sequencing studies yield large candidate gene sets comprising dozens or hundreds of mutated genes. However, few technologies are available for the systematic downstream evaluation of these results to identify novel starting points of future cancer therapies.We improved and extended a site-specific recombination-based system for systematic analysis of the individual functions of a large number of candidate genes. This was facilitated by a novel system for the construction of isogenic constitutive and inducible gain- and loss-of-function cell lines. Additionally, we demonstrate the construction of isogenic cell lines with combinations of the traits for advanced functional in vitro analyses. In a proof-of-concept experiment, a library of 108 isogenic melanoma cell lines was constructed and 8 genes were identified that significantly reduced viability in a discovery screen and in an independent validation screen. Here, we demonstrate the broad applicability of this recombination-based method and we proved its potential to identify new drug targets via the identification of the tumor suppressor DUSP6 as potential synthetic lethal target in melanoma cell lines with BRAF V600E mutations and high DUSP6 expression.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Wittig, Rainer
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Schmidt, Steffen
|b 2
700 1 _ |a Lyer, Stefan
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Bewerunge-Hudler, Melanie
|0 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
|b 4
|u dkfz
700 1 _ |a Gronert-Sum, Sabine
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Strobel-Freidekind, Olga
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Müller, Carolin
|b 7
700 1 _ |a List, Markus
|b 8
700 1 _ |a Jaskot, Aleksandra
|b 9
700 1 _ |a Christiansen, Helle
|b 10
700 1 _ |a Hafner, Mathias
|b 11
700 1 _ |a Schadendorf, Dirk
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Block, Ines
|b 13
700 1 _ |a Mollenhauer, Jan
|b 14
773 _ _ |a 10.18632/oncotarget.15863
|g Vol. 8, no. 14
|0 PERI:(DE-600)2560162-3
|n 14
|p 23760-23774
|t OncoTarget
|v 8
|y 2017
|x 1949-2553
909 C O |p VDB
|o oai:inrepo02.dkfz.de:120588
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOTARGET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOTARGET : 2015
920 1 _ |0 I:(DE-He78)B050-20160331
|k B050
|l Molekulare Genomanalyse
|x 0
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l Microarray Unit
|x 1
920 1 _ |0 I:(DE-He78)L401-20160331
|k L401
|l DKTK Essen
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B050-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a I:(DE-He78)L401-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21